Inflation Reduction Act Mandates: Medicare Price Cuts Threaten Merck

Medicare Price Negotiations Erode Core Profitability

The U.S. Inflation Reduction Act initiates unprecedented government-mandated price smoothing that directly threatens Merck's established profitability model. This systemic policy shift has already forced a severe 79 percent Medicare price cut on the diabetes treatment Januvia in 2026. Management expects Keytruda to face the next round of price negotiations, compounding the pressure as the blockbuster oncology drug approaches its 2028 patent expiration.

Geopolitical Friction Threatens International Vaccine Distribution

Geopolitical tension introduces external vulnerabilities within the company's global supply chain and operational framework. Merck maintains significant commercial exposure to the Chinese market, where its human health vaccines generate crucial revenue. Gardasil sales face heightened sensitivity to regional economic shifts and local competition, while escalating trade tensions could disrupt the international delivery and supply chain consistency of these biologics.

Compounding Pressures Threaten Future Revenue Trajectories

These simultaneous regulatory and geographic challenges pose critical hurdles to Merck's historical growth trajectory. If aggressive biosimilar competition accelerates upon the pending Keytruda exclusivity loss, the company could see up to 30 percent of its total revenue erode rapidly. To mitigate this margin degradation, the corporate defense rests heavily on successfully executing late-stage acquisitions to fill the impending revenue gap.